Skip to content

The Maternal Cellular Immune System and Cytomegalovirus Intrauterine Infection

The Relation Between the Maternal Cellular Immune System and Cytomegalovirus Intrauterine Infection

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01081379
Enrollment
100
Registered
2010-03-05
Start date
2014-02-28
Completion date
2022-08-31
Last updated
2019-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cytomegalovirus Infections, Pregnant Women

Keywords

Cytomegalovirus Infections, Pregnancy, T-Lymphocytes, Transmission

Brief summary

The purpose of this study is to find a correlation between function of cytomegalovirus -specific T cells and the probability for intrauterine transmission.

Detailed description

Fetal infection with CMV is the most common cause of intrauterine infection. Only 40% of pregnant women with primary CMV transmit the virus to their fetus. Many of these women are referred to amniocentesis and many elect to terminate pregnancy without knowledge about fetal infection or damage. Currently it is assumed that transmission is dictated by variety of factors including maternal and fetal immune system. Efforts to find correlation between maternal immune system and fetal infection which can be used as a diagnostic marker were unsuccessful. Our hypothesis is that there is a correlation between cellular immune response of the mother to CMV infection and viral transmission to the fetus. Pregnant women with primary CMV infection (40% of whom are expected to be transmitters)and with pre-conception immunity will participate in this study. Blood from these women will be incubated with CMV peptides and T cell activation will be measured by the secretion of various cytokines.

Interventions

None listed

Sponsors

Shaare Zedek Medical Center
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Pregnant women * CMV IgG sero-conversion or the presence of low avidity IgG antibodies or the presence of IgM with no previous IgG antibodies.

Exclusion criteria

* Underlying immune deficiencies * Other pregnancy complications

Design outcomes

Primary

MeasureTime frame
Maternal-Fetal transmission of CMV1 year

Countries

Israel

Contacts

Primary ContactYechiel Schlesinger, M.D.
s.yechiel@gmail.com972-2-6555-147
Backup ContactYifat Yedidia-Eldar, Ph. D.
yifat4@gmail.com972-26666-775

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026